Show Notes
In this episode of The GLP-1 Podcast Show, I speak with Dr. Catherine Toomer, founder of Total Weight Care Institute and a family medicine physician specializing in metabolic disease. The discussion examines long-term clinical experience using GLP-1 therapies, including dosing strategies, metabolic regulation, and patient-centered obesity care. She also explores insulin resistance, brain signaling, and emerging therapeutic applications. Listen now on all major platforms!
“Appetite regulation is strongly influenced by brain signaling pathways, and correcting metabolic signaling often changes hunger perception and eating behavior without relying on willpower alone.”
Meet the guest: Dr. Catherine Toomer https://www.linkedin.com/in/drtoomer/ is a family medicine physician and founder of Total Weight Care Institute, with more than fifteen years of clinical experience using GLP-1 therapies to address metabolic disease and obesity. Her work focuses on correcting metabolic dysregulation through evidence-based medical strategies and personalized care.
What you will learn: (00:00) Highlight (00:31) Introduction (01:52) Metabolic disease drivers (05:33) Personalized dosing strategy (07:17) Managing side effects (19:44) Brain appetite signaling (22:40) Future applications (24:50) Final Questions
𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺. Website: https://www.wisenetix.com/glp1 Instagram: https://www.instagram.com/theglp1podcast/ LinkedIn: https://www.linkedin.com/showcase/the-glp-1-podcast-show/
More from The GLP-1 Podcast Show
In this episode of The GLP-1 Podcast Show, I speak with Dr. Anders Fink-Jensen, Professor of Psychiatry at the University of Copenhagen and a consultant psychiatrist, about the emerging role of GLP-1 receptor agonists in addiction treatment. We examine the clinical observations that initiated this research, findings from a randomized trial of semaglutide for alcohol use disorder, possible effects on craving, dosing considerations, and the evidence still needed before broader clinical use. Listen now on all major platforms.
In this episode of The GLP-1 Podcast Show, I speak with Dr. Michelle Gordon, a physician board-certified in obesity medicine and CEO of Thrive Span Medical, about obesity care for women in midlife. We discuss how GLP-1 therapy fits into long-term disease management, why slower weight reduction, adequate protein, resistance training, hydration, and fiber matter, and how hormonal changes may affect weight, cognition, and metabolic health. Dr. Gordon also explains when bariatric surgery remains appropriate and why obesity should be treated as a complex chronic disease. Listen now on all major platforms.
In this episode of The GLP-1 Podcast Show, I speak with Dr. Jon Campbell, Associate Professor of Medicine at Duke University, about the changing science of GIP and glucagon. We examine GIP physiology, glucagon signaling, weight-independent metabolic effects, multi-receptor agonism, and variability in treatment response. Discover how emerging pharmacology could shape more precise obesity treatment. Listen now on all major platforms.
In this episode of The GLP-1 Podcast Show, I speak with Dr. Ashley Koff, registered dietitian, founder of The Better Nutrition Program, and bestselling author of Your Best Shot, about weight health in the GLP-1 era. She explains why body composition matters more than total weight, how digestion and hydration shape nutrition outcomes, why protein advice must be personalized, and how clinicians can support more sustainable metabolic health. Listen now on all major platforms.
In this episode of The GLP-1 Podcast Show, I speak with Dr. Timothy Garvey, Endowed Professor of Medicine at the University of Alabama at Birmingham, about complication-centric care for Adiposity-Based Chronic Disease. We examine current obesity guidelines, medication selection according to complications, what the key unmet clinical need is in obesity care, and the role of second-generation GLP-1 medications in type 2 diabetes. Listen now on all major platforms.